BMPR2
Bone morphogenetic protein receptor type-2
As of the edition of 20 October 2026, BMPR2 (bone morphogenetic protein receptor type-2, UniProt Q13873) has 3 drugs tested at it and 1 company on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q13873
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 7
- Disease areas
- Bones, joints and muscles; Mouth and teeth; Nutrition and metabolism; Blood and lymph; Heart and blood vessels; Hormones; Inherited and neonatal; Injuries
- Registered trials of its drugs
- 8
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Withdrawn from market | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Dibotermin alfa | Marketed | Phase 4 | none listed |
| Bone morphogenetic protein 2 | Went quiet | Phase 2 | none listed |
| Eptotermin alfa | Withdrawn from market | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 1 |
| Total on the list | 1 |